The idea of transforming a spinal disc into connective tissue in order to cure discogenic chronic low back pain came to Kjell Olmarker while waiting for a delayed flight. The idea became the basis for Stayble Therapeutics and the injectable drug STA363. The company is now conducting a phase IIb study that follows upon successful phase Ib results. BioStock has spoken with the company's CEO Andreas Gerward about the treatment, the ongoing study, and the company's future prospects.